The Fight Has Moved to Banks and Feeds
The company that developed retatrutide is no longer waiting on federal regulators to shut down the market for copies of its unapproved obesity drug. It is going after the plumbing instead.
Eli Lilly is pressuring credit card companies, payment processors, social media platforms, e-commerce sites, and shipping firms to block advertising and payment processing for vendors selling products marketed as retatrutide. The company laid out that demand publicly on August 12 alongside six new lawsuits, and reporting on the retatrutide black market published Monday by Axios put fresh attention on it. A Lilly spokesperson told the outlet that federal authorities should take the strongest actions the law allows, naming seizures, injunctions, and criminal prosecutions.
The scale of what the company claims to have found is part of the argument. In the company's call on payment processors, Lilly said it has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general, law enforcement, and professional licensing boards. It also said it has reported more than 14,000 websites, advertisements, social media posts, and product listings to internet providers and platforms across more than 100 countries, and that some continue to carry the content. Chief Medical Officer David A. Hyman said what is sold on the black market is "entirely unverified, unapproved, and not worth the risk."
Whether that pressure changes anything for someone scrolling past a peptide ad tonight is the open question. A Department of Health and Human Services official confirmed to Axios that the FDA has sent warning letters to multiple companies and worked with state law enforcement. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, told the outlet that enforcement efforts must be funded, adding that he is "not seeing any stomach in Congress" to give the agency more money.
No Regulator Anywhere Has Reviewed These Products
The core fact has not changed and is worth restating clearly. Retatrutide has not been approved by the FDA or any regulator worldwide, and it is not the subject of any pending application. Lilly said in late July that it is completing the manufacturing and quality control data package required for a biologics license application and plans to submit the drug for approval in the United States in the first quarter of 2027. It remains in Phase 3 trials.
That sequencing is what separates this from familiar counterfeit drug stories. When a fake version of an approved medicine circulates, regulators at least know what the genuine article should contain, how it behaves in the body, and what its safety profile looks like across thousands of trial participants. Here, no regulatory safety review has been completed, so a buyer is absorbing two unknowns at once: whether the vial contains what the label claims, and whether the underlying molecule is safe at the dose being self-administered.
Federal guidance on unapproved GLP-1 drugs used for weight loss states that retatrutide cannot lawfully be compounded because it is not a component of any approved drug product. Sellers work around that by labeling vials for research use only while marketing them to people who intend to inject them. A warning letter documenting that pattern went to an online peptide seller this spring, one of a group of letters in which the agency said website evidence established that the products were intended as drugs for human use.
Poison Center Calls Are the Clearest Household Signal
The most useful independent measure of what is happening inside American homes is not vendor counts. It is poison center data.
Human exposures to retatrutide reported to United States poison centers averaged about 95 per month in the first four months of 2026, a 265 percent increase over the final four months of 2025, according to a CBS News investigation of the market. That reporting also found more than 120 websites selling or promoting the drug and more than 50 clinics staffed by licensed physicians and nurse practitioners openly advertising it. After reporters made contact, at least 21 clinics removed retatrutide from their sites or changed the wording.
Enforcement has been slower. A Public Citizen investigation found that the FDA had sent 14 warning letters to retatrutide vendors since December 2024, and that as of May 2026, 11 of those companies were still advertising the drug or related peptides, while 8 continued selling retatrutide itself. Drawing on the FDA's adverse event reporting system, the group counted 10 reports tied to retatrutide in 2025, four of which involved hospitalization, and 26 reports in the first five months of 2026, 11 of which involved hospitalization and three of which were described as life-threatening. Those reports are unverified and do not establish that authentic retatrutide caused each event.
The financial dimension is not incidental. Vendors advertise vials for as much as $600, a price many buyers absorb precisely because approved obesity medications are expensive or not covered. A household weighing that trade is buying a product with no lot traceability, no recall pathway, no pharmacist review, and no insurance recourse if something goes wrong.
Three Things That Could Change the Picture
Three developments are worth watching, and none of them is a symptom list.
The first is whether payment and platform pressure work where warning letters did not. Cutting off card processing and ad placement is the same lever used against other illicit online markets, and it tends to move faster than litigation. Lilly's six lawsuits, filed in federal courts in California and Texas, name four online peptide sellers, a medical spa, and a compounding pharmacy, and seek permanent injunctions and the return of profits. Axios reported that the company's earlier efforts to get sellers to stop have had little effect so far.
The second is the FDA's own capacity. Warning letters are the opening move in an enforcement sequence that normally escalates to seizures and injunctions, and those steps require coordination with the Justice Department and resources the agency has not committed here.
The third is the approval timeline itself. Nothing about the legal market will change before 2027 at the earliest, which means the gap that created this problem will remain open for at least another year.
MedicalDaily previously reported that clinics and medical spas were selling the unapproved injection to consumers across the country. What is new is where the pressure is now being applied and the acknowledgment from federal and industry figures that agency enforcement alone has not slowed the market.
Anyone currently using a product bought this way should talk to a clinician rather than stopping or adjusting anything on their own, and should say exactly what was injected and at what dose. Approved obesity medications and clinical trial enrollment both remain available through supervised routes.
Key Questions Answered
Is retatrutide approved anywhere? No. It has not been approved by the FDA or any other regulator worldwide, and Lilly says it will not submit a United States application until the first quarter of 2027.
What is Lilly asking for? That payment processors, credit card companies, social media platforms, e-commerce sites, and shipping firms cut off the sellers, and that regulators and law enforcement pursue seizures, injunctions, and criminal prosecutions.
Why does research only appear on these products? Sellers use that label to argue that the product is not being marketed for human use, even as they promote it to people who intend to inject it. Federal officials have described the practice in warning letters.
How many people are being harmed? Poison centers logged about 95 retatrutide exposures per month in early 2026, a 265 percent rise over late 2025. Public Citizen counted 26 adverse event reports in the first five months of the year, 11 of which involved hospitalization.
Can a compounding pharmacy legally make it? No. Federal officials have stated that retatrutide cannot lawfully be compounded because it is not part of any approved drug product.
Is a buyer breaking the law? Enforcement to date has targeted sellers rather than individual purchasers. The more immediate exposure for buyers is in the medical and financial sectors.
What should someone using it now do? Speak with a clinician, disclose exactly what was injected and at what dose, and do not make changes without medical guidance.
